Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.58 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527154 | 0.82 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL17913647 | 0.79 | ALDH1A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL8043039 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL11396901 | 0.79 | CYP19A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL13605931 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1299161 | 0.78 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL2721648 | 0.78 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL195007 | 0.78 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1637980 | 0.78 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5047642 | 0.78 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| CN-103509030-A | Camptothecin compound and preparation and application thereof | LI YULIANG | 2014-01-15 | — | — | CN | disclosed |
| EP-1095040-B1 | NEW BENZOXAZOLES WITH PDE-INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-6376485-B1 | SELECTIVE PHOSPHODIESTERASE INHIBITORS FOR TREATING ASTHMA, BRONCHITIS, AND EMPHYSEMA; HIGH BIOAVAILABILITY AND LOW TOXICITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1095040-A1 | NEW BENZOXAZOLES WITH PDE-INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001695-A1 | NEW BENZOXAZOLES WITH PDE-INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | TOP2A, TOP2B, TYMP | ERN1 2613/4885TLR2 4240/4885TLR1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.